Cerami Chiara, Dubois Bruno, Boccardi Marina, Monsch Andreas U, Demonet Jean Francois, Cappa Stefano F
Vita-Salute San Raffaele University, Milan, Italy; Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy; Clinical Neuroscience Department, San Raffaele Turro Hospital, Milan, Italy.
Dementia Research Center and Department of Neurology, Salpêtrière University Hospital, Paris University, Paris, France.
Neurobiol Aging. 2017 Apr;52:153-166. doi: 10.1016/j.neurobiolaging.2016.03.034.
Although Alzheimer's disease criteria promote the use of biomarkers, their maturity in clinical routine still needs to be assessed. In the light of the oncology framework, we conducted a literature review on measures used to assess delayed recall impairment due to medial temporal lobe dysfunction (i.e., free and cued word list recall tests). Ample evidence is available for phases 1 (rationale for use), 2 (discriminative ability), and 3 (early detection ability) for many of the tests in routine use. Evidence about phase 4 (performance in real world) and phase 5 (quantify impact and costs) is yet to come. Administration procedures have been standardized and cutoff scores are well validated in large Alzheimer's disease and mild cognitive impaired series. Some aspects (e.g., different task formats), however, hamper the comparability of results among different populations and the reproducibility between laboratories. No definite guideline for their use can thus be proposed at the moment. Accordingly, the maturity of such markers is not yet sufficient and requires future investigation to promote the proper use of memory measures in clinical settings.
尽管阿尔茨海默病的诊断标准提倡使用生物标志物，但其在临床常规应用中的成熟度仍有待评估。参照肿瘤学框架，我们对用于评估因内侧颞叶功能障碍导致的延迟回忆受损的方法（即自由及线索词表回忆测试）进行了文献综述。对于许多常规使用的测试，在第1阶段（使用原理）、第2阶段（鉴别能力）和第3阶段（早期检测能力）已有充分证据。关于第4阶段（在现实世界中的表现）和第5阶段（量化影响和成本）的证据尚待出现。管理程序已标准化，临界分数在大型阿尔茨海默病和轻度认知障碍系列中得到了充分验证。然而，某些方面（例如不同的任务形式）妨碍了不同人群之间结果的可比性以及实验室之间的可重复性。因此，目前尚无法提出明确的使用指南。相应地，此类标志物的成熟度仍不足，需要未来的研究以促进记忆测量方法在临床环境中的合理应用。
